Istituto Oncologico della Svizzera Italiana

Sede principale
6500 Bellinzona Via Ospedale
Tel. +41 (0)91 811 94 10
iosi@eoc.ch

Istituto Oncologico della Svizzera Italiana

Sede principale
6500 Bellinzona Via Ospedale
Tel. +41 (0)91 811 94 10
iosi@eoc.ch

Istituto Oncologico della Svizzera Italiana

Clinical Research Back

New Drug Development Unit

The New Drug Development Unit at IOSI is dedicated to the coordination and conduct of Phase I clinical trials and selected Phase II-III clinical trials, aimed at evaluating new drugs and/or innovative therapeutic approaches.
 

Description of the Service

The Unit offers patients the possibility of receiving treatment with experimental drugs, i.e. drugs still in the study phase. Studies are in progress both for patients with solid tumours and for patients with lymphomas and other haematological neoplasms.
 

Service features

The main objective is the co-ordination and management (medical and nursing care of patients included in experimental protocols and data collection) of phase I and selected phase II-III clinical trials active at IOSI.
The New Drug Development Unit has highly qualified medical and nursing staff with long experience in clinical trial management. It collaborates with all units and physicians at IOSI for patients included in clinical trials and with groups outside IOSI for the conduct of multicentre clinical trials.
 

Information for patients

The venue for medical examinations and therapy is the Day Hospital of Clinical Research, at the Ospedale San Giovanni, Bellinzona.
Patients can contact the doctors of the unit directly or through their treating physicians.
Appropriate documentation is requested, and if there is an indication for one of the experimental therapies available, an appointment is made for a medical consultation. Treatment is started only after the patient has evaluated and accepted the therapy proposal (to be carried out at IOSI), the treatment procedures and the checks to be performed.
The patient is informed of the outcome of the therapy, of which the treating doctor is also informed, with whom, if necessary, a new therapy proposal is discussed.
Ongoing studies are listed on the website.
 
For more information on the study characteristics see www.ClinicalTrials.gov
Back